Business Context and Reporting Period
Company: Coherus Oncology, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 17, 2026
Primary Event: Declaration of a special dividend of Contingent Value Rights (CVRs) related to the company's remaining biosimilar assets.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, or margin data. The report focuses on a corporate action regarding asset monetization rather than operational financial performance.
- Debt/Liquidity Context: The Company is party to a Loan and Security Agreement dated August 12, 2026, with Innovatus Life Sciences Lending Fund I, L.P. This agreement contains restrictions on the disposition of the Legacy BioSim Assets and payments under the CVRs.
- Asset Scope: The CVRs cover "Legacy BioSim Assets," including patents, intellectual property, royalties under existing licenses, cell lines, and related regulatory materials.
Material Changes and Corporate Actions
The primary material change is the declaration of a special dividend of CVRs to be distributed to stockholders of record as of 5:00 p.m. Eastern Time on September 30, 2026.
- Distribution Ratio: One CVR will be issued for each share of Common Stock outstanding on the Record Date.
- CVR Term: The term begins on October 7, 2026, and ends on October 7, 2028.
- Payment Trigger: CVR Payments are contingent upon the Company selling, licensing, or disposing of the Legacy BioSim Assets. Payments are calculated based on net cash proceeds actually received.
- Advisory: The Company has retained an investment bank as a capital markets adviser to assist with the sale process for these assets.
Guidance, Outlook, and Risks
Outlook: The Company anticipates monetizing the Legacy BioSim Assets during the CVR term, though no specific valuation or timing for asset sales is provided in this filing.
Risks and Contingencies:
- Contractual Restrictions: The Loan Agreement with Innovatus Life Sciences may restrict the ability to dispose of assets or make CVR payments.
- Uncertainty of Proceeds: CVR payments are not guaranteed and depend entirely on future transactions regarding the Legacy BioSim Assets.
- CVR Limitations: CVRs are non-transferable (except under limited circumstances), unregistered, unlisted, bear no interest, and carry no voting or dividend rights.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks related to capital raising, clinical trials, litigation, and regulatory actions.
Investor Verification Checklist
- Verify the specific terms and restrictions in the Loan and Security Agreement dated August 12, 2026, regarding asset disposition.
- Review the Contingent Value Rights Agreement (Exhibit 99.3) for detailed payment calculation formulas and conditions.
- Confirm the status of the "Legacy BioSim Assets" and any ongoing regulatory or commercial efforts to monetize them.
- Check the Company's most recent Form 10-Q (filed August 5, 2026) for current liquidity and debt covenants not detailed in this 8-K.
- Monitor the Company's website for the FAQ document (Exhibit 99.2) regarding the CVR distribution.